Once-daily use of ofloxacin for prophylaxis in breast cancer surgery

Chemotherapy
K Morimoto, H Kinoshita

Abstract

The 150 consecutive patients who were hospitalized for breast cancer at our department between September 1992 and November 1995 were enrolled in this open study after having given their informed consent. Patients were assigned randomly to receive ofloxacin in daily doses of 200 mg to be taken in a single dose or a total dose of 600 mg divided into three doses postoperatively for 5 days. Ten patients (8 found to be without malignancies) were excluded from evaluation. Wound infections developed in 8 (12%) of the 69 patients in the 200-mg group and 12 (17%) of the 71 patients in the 600-mg group. Postoperative wound care lasted a median of 19 days (25th and 75th percentiles, 15 and 29 days) for patients given 200 mg and 16 days (13 and 25 days) for those given 600 mg; the difference was not statistically significant (Wilcoxon's U test). Signs or symptoms suggesting ofloxacin toxicity were not observed, and several significant differences were found in laboratory test results between the two groups both before and after treatment. Abnormal changes after treatment were found in many individuals, but the rate of occurrence was similar in the two groups (U test). When ofloxacin is used for prophylaxis after breast surgery, we recommen...Continue Reading

Citations

Sep 21, 2005·Breast Cancer Research and Treatment·Marie-Jeanne T F D Baas-Vrancken PeetersPaul J Breslau
Nov 7, 2006·Journal of the American College of Surgeons·Talar TejirianPhilip I Haigh
Mar 13, 2014·The Cochrane Database of Systematic Reviews·Daniel J JonesSophie V Bell-Syer
Sep 27, 2019·The Cochrane Database of Systematic Reviews·Michael GallagherSophie V Bell-Syer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.